Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00485)
Name
Olaparib
Synonyms    Click to Show/Hide the Synonyms of This API
Olaparib; 763113-22-0; AZD2281; Lynparza; KU-0059436; AZD 2281; AZD-2281; Olaparib (AZD2281, Ku-0059436); UNII-WOH1JD9AR8; KU-59436; AZD2281(olaparib); MFCD13185161; WOH1JD9AR8; Olaparib (AZD-2281); C24H23FN4O3; CHEBI:83766; AZ2281; 937799-91-2; KU59436; OLAPARIB cpd; Olaparib [USAN:INN]; Acylpiperazine analogue, 47; Olaparibum; Lynparza (TN); PubChem19148; KU 59436; Olaparib (AZD2281); Olaparib - AZD2281; AZD-2281 (Olaparib); Olaparib (JAN/USAN/INN); MLS006010185; SCHEMBL426568; CHEMBL521686; GTPL7519; BDBM27566; AOB1085; DTXSID60917988; EX-A002; BCPP000360; HMS3295I09; HMS3426C03; HMS3654G13; HMS3746K07; HMS3870H03; BCP01872; ABP000423; ANW-43329; NSC747856; NSC753686; ZINC40430143; AKOS005145764; AC-7939; ACN-032229; AZ-2281; BCP9000363; CCG-264799; CS-0075; DB09074; EX-7210; KEYLYNK-010 COMPONENT OLAPARIB; NSC-747856; NSC-753686; QC-2660; SB14617; SS-4573; AZD2281,Olaparib, KU-0059436; NCGC00238451-01; NCGC00238451-02; NCGC00238451-09; NCGC00238451-11; AK-40514; BR-40514; HY-10162; Olaparib (AZD2281, KU0059436); SMR004701291; SY040527; OLAPARIB COMPONENT OF KEYLYNK-010; AB0009952; Olaparib(AZD2281,KuDOSKU-0059436); BB 0260909; FT-0651458; KU 0059436; SW218142-2; EC-000.2324; D09730; S-3781; S-7836; Z-3275; AZD2281(olaparib)/AZD-2281/KU0059436; J-503540; Q7083106; BRD-K02113016-001-08-9; BRD-K02113016-001-09-7; AZD 2281; KU 0059436; KU 59436; 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine; 1021843-02-6
Clinical Status
Approved
Disease Indication Ovarian cancer ICD-11: 2C73 [1]
PubChem CID
23725625
Formula
C24H23FN4O3
Canonical SMILES
C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
InChI
1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
InChIKey
FDLYAMZZIXQODN-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=23725625"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 434.5 Topological Polar Surface Area 82.1
XlogP 1.9 Complexity 790
Heavy Atom Count 32 Rotatable Bond Count 4
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 5
Full List of Drug Formulations (DFMs) Containing This API
          Olaparib 100 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Mannitol; Ferric oxide yellow; Ferrosoferric oxide; Titanium dioxide; Water; Polyethylene glycol 400; Silicon dioxide; Copovidone k25-31; Hypromelloses
                   Dosage Form Oral Tablet
                   Company AstraZeneca
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [2]
Sodium stearyl fumarate DIG Info Leukemia K562 cells (IC50 = 20.2 ug.mL-1) [3]
Polyethylene glycol 400 DIG Info Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) [4]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
          Olaparib 150 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Mannitol; Ferric oxide yellow; Ferrosoferric oxide; Titanium dioxide; Water; Polyethylene glycol 400; Silicon dioxide; Copovidone k25-31; Hypromelloses
                   Dosage Form Oral Tablet
                   Company AstraZeneca
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [2]
Sodium stearyl fumarate DIG Info Leukemia K562 cells (IC50 = 20.2 ug.mL-1) [3]
Polyethylene glycol 400 DIG Info Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) [4]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [5]
          Olaparib 50 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Potassium acetate; Butyl alcohol; Isopropyl alcohol; Ammonia; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Gellan gum (low acyl); Hypromelloses; Lauroyl peg-32 glycerides; Shellac
                   Dosage Form Oral Capsule
                   Company AstraZeneca
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Potassium acetate DIG Info Free fatty acid receptor 3 (EC50 = 5000 nM) [6]
Isopropyl alcohol DIG Info Lymphoma P388/ADR cells (IC50 = 0.22 uM) [7]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [4]
References
1 FDA label for approved olaparib from the official website of the U.S. Food and Drug Administration.
2 Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258.
3 Synthesis and evaluation of (-)-Massoialactone and analogues as potential anticancer and anti-inflammatory agents. Eur J Med Chem. 2014 Apr 9; 76:291-300.
4 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
5 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.
6 WO patent application no. 2001061359A2, NOVEL ASSAY.
7 Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. J Med Chem. 2004 Mar 11; 47(6):1413-22.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.